For every child

Whoever she is.

Wherever he lives.

Every child deserves a childhood.

A future.

A fair chance.

That’s why UNICEF is there.

For each and every child.

Working day in and day out.

In more than 190 countries and territories.

Reaching the hardest to reach.

The furthest from help.

The most excluded.

It’s why we stay to the end.

And never give up.

unicef | for every child

unicef
for every child

Cervical Cancer Toolkit

UNICEF procurement provides access to a comprehensive range of tools to boost the push to eliminate cervical cancer

2023

Cervical cancer is the fourth most common cancer in women, affecting over half a million and killing more than 300,000 each year. The disease and inflicted tragic losses have far-reaching impact on families, especially children, as many affected women are mothers. But it does not have to be this way. Proven and cost-effective strategies and tools can eliminate cervical cancer.

Availability of a holistic supply solution is critical to enable impactful, sustainable and cost-efficient health programmes and boost the push to eliminate cervical cancer. Responding to this need, and building on technological advances and opportunities, UNICEF has created a unique supply solution, complete of products for prevention, diagnosis, and cervical pre-cancer treatment that are available for procurement for countries and eligible partners.

This overview of products available through UNICEF procurement to support cervical cancer elimination programmes is particularly useful for programme managers, supply managers, experts, policymakers, and donors.

Table of contents |

Background |

UNICEF is a partner in the Cervical Cancer Elimination Initiative, which aims to eliminate cervical cancer as a public health problem by 2030. Achieving this goal relies on three pillars:

Vaccination: More than 95% of cervical cancer cases are caused by the human papillomavirus (HPV), which can be prevented by a safe and effective vaccine. More than 110 countries have introduced the HPV vaccine in their routine immunization programmes, primarily targeting girls 9 to 14 years of age. UNICEF provides countries with HPV vaccines that are affordable, timely and of assured quality.

UNICEF also helps countries achieve high HPV vaccination coverage by providing technical expertise to support national health and immunization programmes, social and behaviour change campaigns, and the immunization supply chain strengthening.

© UNICEF/UN0733686/Magray

Screening: Systematic screening using high-performance tests provides early diagnosis that enables secondary prevention. In collaboration with donors and implementing partners, UNICEF has been delivering quality-assured diagnostic tests for HPV at affordable prices to low– and middle-income countries since 2020. Programmatically, UNICEF supports advocacy to raise awareness about the importance of early diagnosis, provides technical assistance to increase access to testing, and informs governments and partners about diagnostic products available through global supply arrangements.

Treatment: Cervical cancer is curable if detected early and treated adequately. Available treatment primary targets women diagnosed with precancerous lesions. In 2022, UNICEF started delivering affordable, fit-for-purpose portable thermal ablation devices and colposcopes to improve disease management. UNICEF supports efforts to increase awareness about the importance of early treatment of cervical cancer, and informs governments and partners about availability of suitable technologies and products.

Tools for prevention, diagnosis, and treatment of cervical pre-cancer: HPV vaccines, diagnostics for HPV and cervical cancer, and portable treatment devices for cervical pre-cancer are available through UNICEF procurement for eligible programmes and countries.

Human papillomavirus vaccine |

The HPV vaccine was prequalified by the World Health Organization (WHO) in 2009 for the prevention of cervical cancer. WHO recommends that countries introduce HPV vaccination in national immunization programmes as part of a coordinated and comprehensive strategy that includes education and access to quality screening and treatment. HPV vaccination should primarily target girls aged 9 to 14 before becoming sexually active. Vaccination of secondary targets, e.g. girls aged 15 years and older, and boys, is recommended only if such a programme is feasible, affordable and does not divert resources from vaccination of primary target. Key technical and commercial details of HPV vaccines currently available for procurement through UNICEF are presented in Table 1. UNICEF anticipates additional HPV vaccines will become available for procurement in 2023 / 2024 following WHO prequalification.

Table 1 WHO-prequalified HPV vaccines available for procurement through UNICEF

UNICEF material number	Manufacturer	HPV types included	Formulation	No. of doses / vial	Shelf life (months)	VVM	Storage	Shipping[1]	Cold chain volume per dose	Indicative price per dose ($US)[2]	Indicative FCA lead time
S359601	Glaxo SmithKline (Belgium)	Bivalent (16/18)	Liquid	2 dose	60	Type 30	2°- 28° C protect from light; do not freeze	2° to 28° C protect from light; do not freeze	4.8 cm3	Gavi: 5.18 Middle-income countries: 10.25 - 11.40	1 month
S359602	Merck (USA)	Tetravalent (16/18, 6/11 for anogenital warts)[3]	Liquid	1 dose	36	Type 30	2°- 28° C protect from light; do not freeze	2° to 28° C protect from light; do not freeze	15.0 cm3	Gavi: 4.50 Middle-income countries: 13.50 - 26.75	2 months
S359851	Xiamen Innovax (China)	Bivalent (16/18)	Liquid	1 dose	36	Type 14	2°- 28° C protect from light; do not freeze	2° to 28° C protect from light; do not freeze	14.29 cm3	Gavi: 2.90	6 months

[1] Refer to the controlled temperature chain (CTC) designation on the next page.
[2] Price per dose is based on free carrier (FCA) INCOTERMS 2020. Pricing follows a tiered pricing approach and is based on different market segments. Further details on the indicative pricing is available here. However, as UNICEF continuously engages with suppliers to improve pricing, please inquire for updated pricing information.
[3] Merck's HPV-9 is anticipated to become available in the next few years.

Supply and pricing considerations for HPV vaccine |

Constraints in the global HPV vaccine supply are improving with the expansion of the manufacturing capacities of existing suppliers and the entry of new suppliers into the market. Gavi-supported countries are encouraged to submit their applications expeditiously, as there may be additional lead times between the timing of their application and the availability of doses for introduction.

In line with manufacturer arrangements, UNICEF may be able to secure improved pricing for middle-income countries (MICs) when HPV vaccine needs are identified, planned, budgeted, and secured against longer timeline procurement commitments. MICs are therefore advised to forecast and plan their demand and consider long-term commitments.

Storage and transportation considerations for HPV vaccine |

Stability and controlled temperature chain (CTC):

GlaxoSmithKline (GSK) bivalent vaccine: 3 days at temperatures between 8°C and 25°C or for up to 1 day at temperatures between 25°C and 37°C. Vaccines should be discarded if not used at the end of this period.

Merck tetravalent vaccine: 96 hours at storage temperature between 8°C and 40°C. Vaccines should be discarded if not used at the end of this period.

Human papillomavirus and cervical cancer diagnostics |

HPV vaccination does not replace the need for cervical cancer screening. Cytology-based screening and visual methods of identifying precancerous lesions are essential to reduce cervical cancer incidence and mortality. WHO encourages countries to use HPV tests for cervical cancer screening, including HPV DNA and HPV mRNA tests. Where health system resources allow for patient follow-up, a colposcopy offers improved disease management. WHO-prequalified near point-of-care and laboratory-based assays for HPV diagnosis, and portable, handheld colposcopes are available for procurement through UNICEF. Key technical and commercial details of available products are presented in Table 2 and Table 3.

Table 2 WHO prequalified HPV diagnostic assays available for procurement through UNICEF

UNICEF material number	Product description	Delivery level	Manufacturer	Manufacturer's reference	Shelf life	Storage and shipping	Indicative price[1] per test (US$)	Indicative FCA lead time	Comments
S0002149	Xpert HPV Assay/10	Near point-of-care	Cepheid	GXHPV-CE-10	18 months	2°C to 28°C	14.90[2]	30 days	Assay is compatible with all Cepheid GeneXpert platforms.
S0001704	careHPV Test, kit/96	Near point-of-care	Qiagen	614015	12 months	4°C to 25°C	4.95	30 days	Assay is compatible with *care*HPV platforms.
U484650	Abbott RealTime High-Risk HPV assay	Lab-based	Abbott	Multiple	18 months	Amplification reagents stored at -25°C to -15°C. Control reagents stored at -10°C or colder. Reagents and controls are shipped on dry ice.	5.69[3]	60 days	Assay is compatible with Abbott m2000 sp/rt platforms.

[1] Price per test is based on free carrier (FCA) INCOTERMS 2020 unless indicated otherwise. Price per test is indicative. Prices are valid at the time of publication. However, as UNICEF continuously engages with suppliers to improve pricing, please inquire for updated pricing information.
[2] Price per kit and per test is Ex Works (INCOTERMS 2020). Eligibility criteria are applicable to the pricing arrangement.
[3] The assay consists of all reagents and consumables needed to perform a test that are included in the indicated price. Availability and pricing is currently limited to 33 sub-Saharan African countries.

Table 3 Colposcopes available for procurement through UNICEF

UNICEF material number	Product description	Use	Manufacturer	Manufacturer's reference	Indicative price[1] per unit (US$)	Warranty	Storage	Operating conditions	Indicative FCA Lead time
S0004076	Colposcope, portable, incl. tripod & accessories	For use by a medical professional. Operating the device can be self-taught.	Gynius	Gynocular	2,050.00	3 years (after shipment)	-10°C to 70°C <80 % relative humidity	10°C to 40°C <80 % relative humidity	30 days

[1] Price per test is based on free carrier (FCA) INCOTERMS 2020. Prices are valid at the time of publication. However, as UNICEF continuously engages with suppliers to improve pricing, please inquire for updated pricing information.

Portable treatment devices for cervical pre-cancer |

Cervical cancer is curable if *detected early* and *treated adequately*. In consideration of ethical practices within the health system, the scale-up of cervical cancer screening must be matched with an increased capacity to treat patients who have detected lesions. Rapid treatment following diagnosis of cervical pre-cancer is critical to cancer prevention. If treatment is needed and eligibility criteria are met, WHO recommends cryotherapy or thermal ablation. Both treatments are equally effective and safe and can be performed in an outpatient clinic.

Portable treatment tools are well-suited for low-resource settings and enable governments to offer treatment for pre-cancer lesions either within campaign-style screening models or at designated health facilities. Portable thermal ablation devices to treat cervical pre-cancer are available for procurement through UNICEF. Key technical and commercial details of available products for thermal ablation are presented in Table 4.

Table 4 Portable thermal ablation treatment devices available for procurement through UNICEF

UNICEF material number	Product description	Use	Manufacturer	Manufacturer's reference	Indicative price[1] per unit (US$)	Warranty	Storage	Operating conditions	Indicative FCA lead-time
S0004169	Ablation device, thermal, handheld, model 1	The device must be used by a physician or a medical professional under the supervision of a physician.	Liger Medical LLC.	HTU-110	948.13	2 years (after shipment, excluding battery)	-5°C to 45°C <80 % relative humidity	16°C to 45° C <80 % relative humidity	10 - 20 days
S0004172	Ablation device, thermal, handheld, model 2	The device must be used by a physician or a medical professional under the supervision of a physician.	WISAP Medical Technology GmbH.	C3 Set / Option B (6100)	938.00[2]	2 years (after shipment, excluding battery)	5°C to 40°C <85 % relative humidity	10°C to 50°C <85 % relative humidity	10 - 20 days

[1] Price per unit is based on free carrier (FCA) INCOTERMS 2020. Prices are valid at the time of publication. However, they are indicative. As UNICEF continuously engages with suppliers to improve pricing, please inquire for updated pricing information.

[2] Minimum order quantity (5 units) is required for this product

How to access UNICEF procurement |

There are two ways to access HPV vaccines, HPV and cervical cancer diagnostics, and treatment devices for cervical pre-cancer through UNICEF procurement:

1. Governments, UN agencies, philanthropic organizations, non-governmental organizations, and academia in countries of programme cooperation can access UNICEF procurement support through UNICEF Procurement Services. For inquiries and questions on UNICEF Procurement Services please contact psid@unicef.org.

2. UNICEF country offices can initiate procurement through a standard programme-offshore procedure, raising sales orders for UNICEF Supply Division's action. For internal inquiries and questions please contact countrysupport@unicef.org.

UNICEF Supply Division
Oceanvej 10–12
2150 Nordhavn Copenhagen
Denmark

Telephone: +(45) 45 33 55 00
Email: supply@unicef.org

unicef
for every child